Compound News and Research

RSS

Findings point to new therapy against prostate and other cancers

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that a drug candidate with anticancer potential can be activated by one of the body's natural responses to cellular stress. Once activated, the agent can kill prostate cancer cells.

11 Jun 2015

New microfluidic chip could save millions of euros in drug development costs

Scientists in an EU-supported project have developed a microfluidic chip that simultaneously analyses the reactions of several human organ tissues when they come into contact with candidates for new drugs.

10 Jun 2015

GSU scientists design new MRI technique for early detection of liver tumors

Scientists at Georgia State University with funding from the National Institute of Biomedical Imaging and Bioengineering have designed an imaging technique to detect early-stage liver tumors, and have proven it successful in mice.

10 Jun 2015

UC Davis research paves way for designing more effective drugs to relieve pain

UC Davis researchers have identified the molecular interactions that allow capsaicin to activate the body's primary receptor for sensing heat and pain, paving the way for the design of more selective and effective drugs to relieve pain. Their study appeared online June 8 in the journal Nature Chemical Biology.

10 Jun 2015

Brain protein key to binge drinking? An interview with Dr. Candice Contet

Alcohol binge drinking is mostly driven by positive reinforcement, a process in which a rewarding experience (e.g., the euphoria one feels when intoxicated) strengthens the behaviour leading to this experience (e.g., going to a bar).

9 Jun 2015

Study suggests direct biophysical link between chronic pain, depression and anxiety

Brain inflammation caused by chronic nerve pain alters activity in regions that regulate mood and motivation, suggesting for the first time that a direct biophysical link exists between long-term pain and the depression, anxiety and substance abuse seen in more than half of these patients, UC Irvine and UCLA researchers report.

9 Jun 2015

Global RA treatment market expected to increase just over $19 billion by 2020

Analysis from business intelligence provider GBI Research - Rheumatoid Arthritis Market to 2020 - says that the global Rheumatoid Arthritis (RA) treatment market is expected to increase in value, from $14.3 billion in 2013 to just over $19 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 4.1%.

8 Jun 2015

Profil Institute for Clinical Research forms strategic partnership with Gubra

Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a strategic collaboration with Gubra ApS, a metabolic preclinical and drug discovery company, to combine expertise and resources to discover and translate into clinical research novel drug targets, compounds and biomarkers addressing metabolic disease.

4 Jun 2015

New finding may lead to development of immunity-based therapies for tuberculosis

A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.

2 Jun 2015

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

MorphoSys AG today published first safety and efficacy data on its proprietary drug candidate MOR202. The data are from a phase 1/2a study in 42 heavily pretreated patients with relapsed/refractory multiple myeloma.

2 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

NSCLC treatment market forecast to reach $7.9 billion by 2020

The Non-Small Cell Lung Cancer treatment market will be driven primarily by the introduction of numerous premium therapies, particularly in second-line and squamous cell treatment settings, which either replace or combine with generic chemotherapies.

2 Jun 2015

Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago.

1 Jun 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Fragrance chemical linalyl acetate could cause allergic eczema

Linalyl acetate, a fragrance chemical that is one of the main constituents of the essential oil of lavender, is not on the list of allergenic compounds pursuant to the EU Cosmetics Directive. Thus, it does not need to be declared on cosmetic products sold within the EU. Recent studies at the University of Gothenburg have shown that linalyl acetate can cause allergic eczema.

30 May 2015

New ground-breaking initiative aims to find new treatments for leishmaniasis and Chagas disease

The Drugs for Neglected Diseases initiative and four pharmaceutical firms, Eisai Co Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Ltd, and AstraZeneca plc have announced the start of a ground-breaking initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.

30 May 2015

Global market for asthma treatment expected to reach $21.7 billion by 2020

Despite generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), the global market for asthma treatment is set to witness moderate growth by the end of the decade.

29 May 2015

Study expands understanding of the production of ET-743 compound

For decades, scientists have known that ET-743, a compound extracted from a marine invertebrate called a mangrove tunicate, can kill cancer cells. The drug has been approved for use in patients in Europe and is in clinical trials in the U.S.

29 May 2015

Compound News and Research

Findings point to new therapy against prostate and other cancers

New microfluidic chip could save millions of euros in drug development costs

GSU scientists design new MRI technique for early detection of liver tumors

UC Davis research paves way for designing more effective drugs to relieve pain

Brain protein key to binge drinking? An interview with Dr. Candice Contet

Study suggests direct biophysical link between chronic pain, depression and anxiety

Global RA treatment market expected to increase just over $19 billion by 2020

Profil Institute for Clinical Research forms strategic partnership with Gubra

New finding may lead to development of immunity-based therapies for tuberculosis

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

NSCLC treatment market forecast to reach $7.9 billion by 2020

Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Fragrance chemical linalyl acetate could cause allergic eczema

New ground-breaking initiative aims to find new treatments for leishmaniasis and Chagas disease

Global market for asthma treatment expected to reach $21.7 billion by 2020

Study expands understanding of the production of ET-743 compound

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News